Study examines risk factors for visual impairment among preschool children born extremely preterm

June 11, 2012

Cerebral damage and retinopathy of prematurity appear to be independently associated with visual impairment among preschool children who were born extremely premature, according to a report published Online First by Archives of Ophthalmology.

Retinopathy of prematurity (ROP; an eye disease in very ) is considered the main cause of visual impairment in extremely , however cerebral damage is also a cause of visual impairment (often referred to as cerebral visual impairment) among extremely preterm children, according to background information in the study.

To examine the importance of cerebral damage and retinopathy of prematurity for visual impairment in preschool children who were born extremely premature, Carina Slidsborg, M.D., from Copenhagen University Hospital, Glostrup Hospital and Rigshospitalet, Denmark, and colleagues conducted a clinical follow-up study of a Danish national cohort of children.

The authors included 178 extremely premature children ( <28 weeks) born between February 13, 2004 and March 23, 2006, and a matched control group of 56 term-born children (gestational age 37 to <42 weeks) in the analysis.

Analysis found that global developmental deficits (an indicator for cerebral damage) and foveal sequelae (abnormalities involving the fovea, a small area of the retina responsible for sharp vision) occurred more often in extremely preterm children than in term-born children, and increased with ROP severity. The authors also found that global developmental deficits, moderate to severe foveal abnormality, and ROP treatment were independently associated with .

"In conclusion, we herein demonstrate that, in Denmark, cerebral damage and ROP sequelae are independent risk factors for VA loss among born extremely premature and that the presence of cerebral damage is the primary risk factor of the two," the authors conclude.

Explore further: Lung function of moderately premature babies is reduced at 8-9 years but may improve with age

More information: Arch Ophthalmol. Published online June 11, 2012. doi:10.1001/archophthalmol.2012.1393

Related Stories

Recommended for you

New gene therapy for vision loss proven safe in humans

May 16, 2017

In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.